Regeneron and Sanofi Start U.S. Studies Assessing Arthritis Drug As Coronavirus Treatment
March 16 2020 - 11:10AM
Dow Jones News
By Joseph Walker
Drugmakers Regeneron Pharmaceuticals and Sanofi have launched a
U.S. clinical trial of their rheumatoid-arthritis drug Kevzara in
hospitalized patients with serious complications from Covid-19, the
companies said Monday.
Kevzara wouldn't treat the underlying coronavirus known as
SARS-CoV-2, but it could help reduce disease symptoms like fever
and low blood-oxygen levels. Kevzara suppresses the body's
inflammatory immune response to the virus, which scientists
hypothesize may be overactive in patients with severe illness.
The Wall Street Journal reported on plans for the study last
week.
The study will start out at medical centers in New York,
including Mount Sinai and Northwell Health, and enroll up to 400
patients, a Regeneron spokeswoman said. The study's first stage
will evaluate the drug's ability to reduce fever and supplemental
oxygen, compared with placebo.
(END) Dow Jones Newswires
March 16, 2020 10:55 ET (14:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024